PTEN and prostate carcinoma: In conclusion, unlike p53 that was incapacitated in LNCaP, the Ca/phospholipid-binding WT-ANXA7 revived the PTEN/FOXO3A-associated cell survival control in these PTEN-deficient and androgen-sensitive prostate cancer cells.